This is the authors' abstract. We don't add key points for this paper.
A binding partner designed for uric acid inhibits its precipitation and ionization, and shows an anti-hyperuricemia activity in vivo competitive with benzbromarone, as well as a favorable safety profile.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: